Single-cell technologies reveals subpopulations of microglia that play distinct roles in diseased and healthy brains.

Tiny but powerful nanobodies may be the innovation that snuffs out the pandemic.

A lackluster performance in clinical trials of the monoclonal antibody aducanumab has left some experts unconvinced of its benefit.

Author Lauren Aguirre finds reasons for optimism in the fight against Alzheimer’s disease.

Authors of a new review urge researchers to consider how the chromosomal sex of a cell affects experiments in research on neurodegeneration.

Patients who received the drug fared better cognitively and functionally than those taking placebo, but still experienced losses in performance.

Manipulating the production of new neurons can improve cognition in animal models of the disease, raising the possibility that figuring out a way for humans to make more neurons could make a difference for people with dementia.

Knocking out the receptor for a lipid that causes inflammation rejuvenates macrophage metabolism and restores cognitive function in an Alzheimer’s disease model.

The variant causes a buildup of BACE1 protein in axons in cultured neurons and mice. Researchers say it might be time to rethink failed trials that inhibit BACE1 to treat the neurodegenerative disease.

The test will be a cheaper and more accessible alternative to currently available diagnostic tools, researchers say.

An imaging agent reveals aggregated tau protein in the brain during PET scans and could improve the diagnosis of neurodegenerative diseases, particularly tauopathies.

Surviving Stress: The mysteries of neuronal survival and neurodegeneration

These “coarse-grained” plaques resemble those that clog up the brain’s blood vessels in a different disease, pointing to links between the vascular system and the neurodegenerative disease.

After six months, patients with fast-progressing amyotrophic lateral sclerosis who had received the experimental treatment had less loss of function than those who received a placebo.

The Salk professor developed the institute’s first neurobiology lab and used it to develop cell lines, describe amyloid β toxicity, and screen for compounds that protect against neurodegeneration.

New studies show that elevated levels of a form of tau called p-tau217 can accurately distinguish Alzheimer’s disease from other forms of dementia, and perhaps even predict it.

The authors propose that the shots might keep the immune system primed to battle diseases that would otherwise contribute to cognitive decline.

The cell conversion strategy restores neurons and motor functions lost as a result of an induced Parkinson’s-like illness in the animals.

Experts will explore how RNAi mechanisms can modulate gene expression for the treatment of neurodegenerative diseases and how new methods for their use are being developed.